story of the week
Addition of Bevacizumab to Endocrine Therapy as First-Line Treatment for HR+ Metastatic Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
European Journal of Cancer
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Evaluating the Addition of Bevacizumab to Endocrine Therapy as First-Line Treatment for Hormone Receptor-Positive Metastatic Breast Cancer: A Pooled Analysis From the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) Trials
Eur. J. Cancer 2019 Jul 02;117(xx)91-98, M Martín, S Loibl, T Hyslop, J De la Haba-Rodríguez, B Aktas, CT Cirrincione, K Mehta, WT Barry, S Morales, LA Carey, JA Garcia-Saenz, A Partridge, N Martinez-Jañez, O Hahn, E Winer, A Guerrero-Zotano, C Hudis, M Casas, C Rodriguez-Martin, J Furlanetto, E Carrasco, MN DicklerFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.